

Table 1. Demographic and disease patient characteristics.

	Total (n=422)	No DMARDs (n=25)	csDMARDs (n=108)	b/tsDMARDs (n=289)
Age (years), mean (SD)	58.2 (13.3)	61.1 (13.7)	56 (13.8)	58.8 (13)
Females, n (%)	344 (81.5)	20 (80)	86 (80)	238 (82)
BMI, mean (SD)	24.1 (4.5)	25.3 (3.6)	24.3 (4.6)	24 (4.5)
Current smokers, n (%)	108 (27.3)	5 (20)	14 (13)	89 (31)
Past smokers, n (%)	114 (28.9)	7 (28)	37 (34)	70 (24)
Disease duration, (yrs), mean (SD)	16.1 (11.5)	19.8 (19.5)	14.3 (11.8)	16.4 (10.3)
RF positivity, n (%)	251 (59.5)	12 (41.4)	52 (49.1)	187 (62.5)
ACPA positivity, n (%)	230 (54.5)	10 (34.5)	49 (46.2)	171 (59.6)
Corticosteroids, n (%)	204 (48.3)	8 (32)	59 (55)	137 (47)
DAS28-CRP, median (IQR)	2.3 (1.6-3.2)	2 (1.6-3.7)	2.3 (1.7-3.2)	2.3 (1.6-3.2)
SDAI, median (IQR)	6 (3-12)	6 (3.7-16.3)	5.8 (3.1-12.1)	6 (3-11.8)
GH (0-100), median (IQR)	70 (50-85)	60 (50-80)	70 (55-86)	70 (50-85)
PaGA (0-10), median (IQR)	3 (1.5-5)	4 (2-5)	3 (1.5-4.5)	3 (1.5-5)
PhGA (0-10) median (IQR)	1 (0-4)	2 (0-5)	1 (0-4)	1 (0-3)
ESR mm/h, median (IQR)	14 (7-28)	14 (8-27)	16 (8-30)	12 (5-28)
CRP mg/L, median (IQR)	2.2 (0.5-7)	2.1 (0.6-6.6)	2 (0.4-5)	2.8 (0.6-9)
SJC, median (IQR)	0 (0-1)	0 (0-0)	0 (0-1)	0 (0-1)
TJC, median (IQR)	0 (0-2)	0 (0-4)	1 (0-2)	0 (0-2)

csDMARDs: conventional synthetic Disease Modifying anti-Rheumatic Drugs; tsDMARDs: targeted synthetic-DMARDs; bDMARDs: biological-DMARDs; BMI: body mass index; SD: standard deviation; IQR: interquartile range; RF: rheumatoid factor; ACPA: anti-citrullinated protein antibody; DAS28-CRP: Disease Activity Score in 28 joints using C-reactive protein; SDAI: Simplified Disease Activity Index; GH: general health; PaGA: patient's general assessment; PhGA: physician's general assessment; ESR: erythrocyte